Evidence map›Paper›PMID 28766595›Full record

ArticleChemical communications (Cambridge, England)2017

Design, synthesis, and evaluation of heparan sulfate mimicking glycopolymers for inhibiting heparanase activity.

Ravi S Loka, Fei Yu, Eric T Sletten, Hien M Nguyen

Abstract read
In one paragraph

Article in Chemical communications (Cambridge, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Synthetic Heparanase Inhibitors Can Prevent Herpes Simplex Viral Spread.Angewandte Chemie (International ed. in English) · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ravi S LokaDepartment of Chemistry, University of Iowa, Iowa City, Iowa 52242, USA. hien-nguyen@uiowa.edu.
Fei Yu
Eric T Sletten
Hien M Nguyen
University of Iowa · US

Funding

Tailoring Structures of Sulfated Oligosaccharides for Modulating Heparanase ActivityR01GM098285 · NIGMS · WAYNE STATE UNIVERSITY · PI NGUYEN, HIEN M · 2012 to 2022
$3.5M
NIGMS NIH HHS R01 GM098285
6 · The paper itself

Abstract

Heparanase is an enzyme which cleaves heparan sulfate (HS) polysaccharides of the extracellular matrix. It is a regulator of tumor behavior, plays a key role in kidney related diseases and autoimmune diabetes. We report herein the use of computational studies to extract the natural HS-heparanase interactions as a template for the design of HS mimicking glycopolymers. Upon evaluation, a glycopolymer with 12 repeating units was determined to be the most potent inhibitor and to have tight-binding characteristics. This glycopolymer also lacks anticoagulant activity.

Indexed as

Biomimetic MaterialsEnzyme InhibitorsFactor Xa InhibitorsGlucuronidaseHeparanaseHeparan SulfateMolecular Docking SimulationPolysaccharidesProthrombinEnzyme InhibitorsFactor IIaFactor Xa InhibitorsGlucuronidaseHeparanaseHeparan SulfatePolysaccharidesProthrombin

Identifiers

PMID28766595
PMCPMC5590105
OpenAlexW2737627391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.